165 related articles for article (PubMed ID: 29150742)
1. Associations Between Nucleus Size, and Immunohistochemical Galectin-3, Cytokeratine-19 and Hbme-1 Markers in Thyroid Papillary Carcinoma: A Morphometric Analyze.
Toy H; Etli O; Celik ZE; Sezgin Alikanoglu A
Pathol Oncol Res; 2019 Jan; 25(1):401-408. PubMed ID: 29150742
[TBL] [Abstract][Full Text] [Related]
2. [Usefulness of CK19, HBME-1 and galectin-3 expressions in differential diagnosis of thyroid papillary microcarcinoma from benign lesions].
Tong J; Wang Y; Da JP
Zhonghua Zhong Liu Za Zhi; 2011 Aug; 33(8):599-604. PubMed ID: 22325220
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic significance of CK19, RET, galectin-3 and HBME-1 expression for papillary thyroid carcinoma.
Zhu X; Sun T; Lu H; Zhou X; Lu Y; Cai X; Zhu X
J Clin Pathol; 2010 Sep; 63(9):786-9. PubMed ID: 20644217
[TBL] [Abstract][Full Text] [Related]
4. Combined immunostaining with galectin-3, fibronectin-1, CITED-1, Hector Battifora mesothelial-1, cytokeratin-19, peroxisome proliferator-activated receptor-{gamma}, and sodium/iodide symporter antibodies for the differential diagnosis of non-medullary thyroid carcinoma.
Liu YY; Morreau H; Kievit J; Romijn JA; Carrasco N; Smit JW
Eur J Endocrinol; 2008 Mar; 158(3):375-84. PubMed ID: 18299472
[TBL] [Abstract][Full Text] [Related]
5. Role of cd56 and e-cadherin expression in the differential diagnosis of papillary thyroid carcinoma and suspected follicular-patterned lesions of the thyroid: the prognostic importance of e-cadherin.
Ceyran AB; Şenol S; Şimşek BÇ; Sağıroğlu J; Aydın A
Int J Clin Exp Pathol; 2015; 8(4):3670-80. PubMed ID: 26097548
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical expression of HBME-1 and galectin-3 in the differential diagnosis of follicular-derived thyroid nodules.
Abd-El Raouf SM; Ibrahim TR
Pathol Res Pract; 2014 Dec; 210(12):971-8. PubMed ID: 25041837
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic value of HBME-1, CD56, Galectin-3 and Cytokeratin-19 in papillary thyroid carcinomas and thyroid tumors of uncertain malignant potential.
Nechifor-Boilă A; Cătană R; Loghin A; Radu TG; Borda A
Rom J Morphol Embryol; 2014; 55(1):49-56. PubMed ID: 24715165
[TBL] [Abstract][Full Text] [Related]
8. Ultrasound Risk Assessment Combined with Molecular Markers of Galectin-3, c-MET, HBME-1 and CK19 for Diagnosis of Malignant and Benign Thyroid Nodules.
Han RL; Wang J; Zhang FJ; Zhao N; Gao BL
Pathol Oncol Res; 2019 Jul; 25(3):1075-1081. PubMed ID: 30361909
[TBL] [Abstract][Full Text] [Related]
9. Thyroid tumors of uncertain malignant potential: morphologic and imunohistochemical analysis of 29 cases.
Nechifor-Boila A; Borda A; Sassolas G; Hafdi-Nejjari Z; Cătană R; Borson-Chazot F; Berger N; Decaussin-Petrucci M
Pathol Res Pract; 2015 Apr; 211(4):320-5. PubMed ID: 25595997
[TBL] [Abstract][Full Text] [Related]
10. [Expression of Twist in papillary thyroid carcinomas and its roles in differential diagnosis].
He CN; He L; Cheng JQ; Chen SC; Zhao HF; Zhai JP; Zhang J
Zhonghua Bing Li Xue Za Zhi; 2008 Jan; 37(1):35-9. PubMed ID: 18509983
[TBL] [Abstract][Full Text] [Related]
11. Cyclin D1 in well differentiated thyroid tumour of uncertain malignant potential.
Lamba Saini M; Weynand B; Rahier J; Mourad M; Hamoir M; Marbaix E
Diagn Pathol; 2015 Apr; 10():32. PubMed ID: 25907675
[TBL] [Abstract][Full Text] [Related]
12. Combined staining for immunohistochemical markers in the diagnosis of papillary thyroid carcinoma: improvement in the sensitivity or specificity?
Wu G; Wang J; Zhou Z; Li T; Tang F
J Int Med Res; 2013 Aug; 41(4):975-83. PubMed ID: 23857157
[TBL] [Abstract][Full Text] [Related]
13. Expression of papillary thyroid carcinoma-associated molecular markers and their significance in follicular epithelial dysplasia with papillary thyroid carcinoma-like nuclear alterations in Hashimoto's thyroiditis.
Ma H; Yan J; Zhang C; Qin S; Qin L; Liu L; Wang X; Li N
Int J Clin Exp Pathol; 2014; 7(11):7999-8007. PubMed ID: 25550843
[TBL] [Abstract][Full Text] [Related]
14. [Expression of GADD153 in follicular tumors of thyroid and comparison with CK19, Galectin-3 and HBME-1].
Tang QS; Teng XD; Ding W; Zhou J; Yao HT; Ying LX; Xu LM
Zhonghua Bing Li Xue Za Zhi; 2011 Nov; 40(11):745-8. PubMed ID: 22336157
[TBL] [Abstract][Full Text] [Related]
15. Defining the value of CD56, CK19, Galectin 3 and HBME-1 in diagnosis of follicular cell derived lesions of thyroid with systematic review of literature.
Dunđerović D; Lipkovski JM; Boričic I; Soldatović I; Božic V; Cvejić D; Tatić S
Diagn Pathol; 2015 Oct; 10():196. PubMed ID: 26503236
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical study of papillary thyroid carcinoma and possible papillary thyroid carcinoma-related benign thyroid nodules.
Mai KT; Ford JC; Yazdi HM; Perkins DG; Commons AS
Pathol Res Pract; 2000; 196(8):533-40. PubMed ID: 10982016
[TBL] [Abstract][Full Text] [Related]
17. Distinction between papillary thyroid hyperplasia and papillary thyroid carcinoma by immunohistochemical staining for cytokeratin 19, galectin-3, and HBME-1.
Casey MB; Lohse CM; Lloyd RV
Endocr Pathol; 2003; 14(1):55-60. PubMed ID: 12746563
[TBL] [Abstract][Full Text] [Related]
18. Thyroid peroxidase and galectin-3 immunostaining in differentiated thyroid carcinoma with clinicopathologic correlation.
Savin S; Cvejic D; Isic T; Paunovic I; Tatic S; Havelka M
Hum Pathol; 2008 Nov; 39(11):1656-63. PubMed ID: 18657294
[TBL] [Abstract][Full Text] [Related]
19. Contribution of immunocytochemical stainings for galectin-3, CD44, and HBME1 to fine-needle aspiration cytology diagnosis of papillary thyroid carcinoma.
Das DK; Al-Waheeb SK; George SS; Haji BI; Mallik MK
Diagn Cytopathol; 2014 Jun; 42(6):498-505. PubMed ID: 24273003
[TBL] [Abstract][Full Text] [Related]
20. Differential diagnostic significance of HBME-1, CK19 and S100 in various thyroid lesions.
Palo S; Biligi DS
Malays J Pathol; 2017 Apr; 39(1):55-67. PubMed ID: 28413206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
